Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL494780 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA | |
| SCHEMBL494876 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA | |
| SCHEMBL495153 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA | |
| SCHEMBL493825 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA | |
| SCHEMBL20511325 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA | |
| SCHEMBL495444 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA | |
| SCHEMBL493914 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA | |
| SCHEMBL495124 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA | |
| SCHEMBL494673 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA | |
| SCHEMBL495629 | 1.00 | CA1 (0.65) | CA1CA2L3MBTL1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418030-B1 | CURING AGENT COMPOSITION | KAO CORP (JP) | 2019-09-25 | — | — | EP | claimed |
| CN-102387877-A | Curing agent composition | KAO CORP | 2012-03-21 | — | — | CN | claimed |
| US-20120043694-A1 | CURING AGENT COMPOSITION | KAO CORPORATION (JP) | 2012-02-23 | — | — | US | claimed |
| EP-2418030-A1 | CURING AGENT COMPOSITION | Kao Corporation (JP) | 2012-02-15 | — | — | EP | claimed |
| EP-2418030-B1 | CURING AGENT COMPOSITION | KAO CORP (JP) | 2019-09-25 | — | — | EP | disclosed |
| EP-2581148-B1 | PROCESS FOR PRODUCTION OF MOLDS | KAO CORP (JP) | 2018-10-24 | — | — | EP | disclosed |
| CN-102665961-B | Process for production of molds | KAO CORP | 2015-05-27 | — | — | CN | disclosed |
| US-8729152-B2 | Curing agent composition | KAO CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| EP-2581148-A1 | PROCESS FOR PRODUCTION OF MOLDS | Kao Corporation (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20120261087-A1 | PROCESS FOR PRODUCING A MOLD | KAO CORPORTATION (JP) | 2012-10-18 | — | — | US | disclosed |
| CN-102665961-A | Process for production of molds | KAO CORP | 2012-09-12 | — | — | CN | disclosed |
| CN-102387877-A | Curing agent composition | KAO CORP | 2012-03-21 | — | — | CN | disclosed |
| US-20120043694-A1 | CURING AGENT COMPOSITION | KAO CORPORATION (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2418030-A1 | CURING AGENT COMPOSITION | Kao Corporation (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120043694-A1 | CURING AGENT COMPOSITION | ERG28, SMARCA5, MYB | CA1 2337/4885CA2 3521/4885L3MBTL1 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.